HBL – Hadasit Bio - Holdings Ltd.
(The Company)
January 21, 2015
|
To
The Israel Securities Authority
www.isa.gov.il
|
To
The Tel Aviv Stock Exchange Ltd.
www.tase.co.il
|
Re: A report from D Pharm Company Ltd. – the results of a rights issue
The company is pleased to inform that the D Pharm Company Ltd., a company traded on the Tel Aviv Stock Exchange (herein: D Pharm), has published today through an immediate report, the results of a rights issue according to an off the shelf report offer published by D Pharm on December 25, 2014 (ref no. 2014–01–231303) (herein: the rights issue).
According to the said D Pharm immediate report, the immediate gross proceeds received by D Pharm for the rights realized in the rights issue amount to be approximately 12,775 thousands NIS.
The D Pharm Company’s holdings rate after the rights issue is 5.57% (5.55% in full dilution).
For more information about the results of the rights issue, please see the immediate report form the D Pharm Company from today (ref no. 2015–01–015937).
With Regards,
HBL – Hadasit Bio - Holdings Ltd.
By: Ms. Tamar Kfir, CEO
| 
